Header Logo

Connection

SALIM VIRANI to Cholesterol, LDL

Back to Details
This is a "connection" page, showing publications SALIM VIRANI has written about Cholesterol, LDL.
SALIM VIRANI
Connection Strength
11.595
Cholesterol, LDL
  1. Trends in Patient-Recalled Targets for Cardiovascular Risk Factors in Ambulatory US Adults With Diabetes Mellitus (from National Health and Nutrition Examination Survey). Am J Cardiol. 2022 02 01; 164:143-145.
    View in: PubMed
    Score: 0.598
  2. Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session. Curr Atheroscler Rep. 2020 06 18; 22(8):32.
    View in: PubMed
    Score: 0.541
  3. Impact of Lipid Monitoring on Treatment Intensification of Cholesterol Lowering Therapies (from the Veterans Affairs Healthcare System). Am J Cardiol. 2020 03 15; 125(6):874-879.
    View in: PubMed
    Score: 0.524
  4. The 2018 Cholesterol Management Guidelines: Topics in Secondary ASCVD Prevention Clinicians Need to Know. Curr Atheroscler Rep. 2019 04 02; 21(6):20.
    View in: PubMed
    Score: 0.498
  5. Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial. Circulation. 2019 01 15; 139(3):410-412.
    View in: PubMed
    Score: 0.490
  6. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol =190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry. Circ Cardiovasc Qual Outcomes. 2018 05; 11(5):e004652.
    View in: PubMed
    Score: 0.467
  7. Lipoprotein(a) and cardiovascular disease: current state and future directions for an enigmatic lipoprotein. Front Biosci (Landmark Ed). 2018 01 01; 23(6):1099-1112.
    View in: PubMed
    Score: 0.456
  8. Harder-to-Treat Patients: Recognizing Them and Adapting Treatment Strategies. Am J Cardiol. 2016 Sep 15; 118(6 Suppl):13A-8A.
    View in: PubMed
    Score: 0.417
  9. Decrease the incentives to order lipid panels--reply. JAMA Intern Med. 2014 Mar; 174(3):473-4.
    View in: PubMed
    Score: 0.350
  10. Correlates of repeat lipid testing in patients with coronary heart disease. JAMA Intern Med. 2013 Aug 12; 173(15):1439-44.
    View in: PubMed
    Score: 0.337
  11. Barriers to non-HDL cholesterol goal attainment by providers. Am J Med. 2011 Sep; 124(9):876-80.e2.
    View in: PubMed
    Score: 0.294
  12. Frequency and correlates of treatment intensification for elevated cholesterol levels in patients with cardiovascular disease. Am Heart J. 2011 Oct; 162(4):725-732.e1.
    View in: PubMed
    Score: 0.294
  13. Institutional, provider, and patient correlates of low-density lipoprotein and non-high-density lipoprotein cholesterol goal attainment according to the Adult Treatment Panel III guidelines. Am Heart J. 2011 Jun; 161(6):1140-6.
    View in: PubMed
    Score: 0.288
  14. Non-HDL cholesterol as a metric of good quality of care: opportunities and challenges. Tex Heart Inst J. 2011; 38(2):160-2.
    View in: PubMed
    Score: 0.281
  15. Individual Variation in the Distribution of Apolipoprotein B Levels Across the Spectrum of LDL-C or Non-HDL-C Levels. JAMA Cardiol. 2024 Aug 01; 9(8):741-747.
    View in: PubMed
    Score: 0.180
  16. Prevalence, Awareness, and Treatment of Elevated LDL Cholesterol in US Adults, 1999-2020. JAMA Cardiol. 2023 12 01; 8(12):1185-1187.
    View in: PubMed
    Score: 0.172
  17. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress. Curr Atheroscler Rep. 2023 12; 25(12):965-978.
    View in: PubMed
    Score: 0.171
  18. The Clinical Efficacy and Safety of Bempedoic Acid in Patients at Elevated Risk of Cardiovascular Disease: A Meta-Analysis of Randomized Clinical Trials. Cardiovasc Drugs Ther. 2024 Dec; 38(6):1415-1420.
    View in: PubMed
    Score: 0.166
  19. Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American College of Cardiology Conference. Curr Atheroscler Rep. 2023 06; 25(6):309-321.
    View in: PubMed
    Score: 0.165
  20. The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Preventive Cardiology. J Clin Lipidol. 2023 Mar-Apr; 17(2):208-218.
    View in: PubMed
    Score: 0.163
  21. Discordance Between Standard Equations for Determination of LDL?Cholesterol in Patients With?Atherosclerosis. J Am Coll Cardiol. 2022 02 15; 79(6):530-541.
    View in: PubMed
    Score: 0.152
  22. Association of Low-Density Lipoprotein Testing After an Atherosclerotic Cardiovascular Event with Subsequent Statin Adherence and Intensification. Am J Med. 2022 05; 135(5):603-606.
    View in: PubMed
    Score: 0.150
  23. Association of PCSK9 Variants With the Risk of Atherosclerotic Cardiovascular Disease and Variable Responses to PCSK9 Inhibitor Therapy. Curr Probl Cardiol. 2022 Jul; 47(7):101043.
    View in: PubMed
    Score: 0.149
  24. Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the Veteran's Affairs healthcare system. J Clin Lipidol. 2021 Nov-Dec; 15(6):832-839.
    View in: PubMed
    Score: 0.148
  25. High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. Mayo Clin Proc. 2021 10; 96(10):2660-2670.
    View in: PubMed
    Score: 0.147
  26. Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH). J Clin Lipidol. 2021 Sep-Oct; 15(5):649-652.
    View in: PubMed
    Score: 0.146
  27. Gender Differences in Premature Coronary Artery Disease (from the National Data from the NHANES Database). Am J Cardiol. 2021 08 15; 153:142-144.
    View in: PubMed
    Score: 0.145
  28. Real-world data, theoretical application of guidelines, cost, and access: how do we optimize non-statin therapy for LDL-C/non-HDL-C/ApoB? Eur Heart J. 2020 10 21; 41(40):3910-3912.
    View in: PubMed
    Score: 0.139
  29. Intensity of Lipid Lowering With Statin Therapy in Patients With Cerebrovascular Disease Versus Coronary Artery Disease: Insights from the PALM Registry. J Am Heart Assoc. 2019 10; 8(19):e013229.
    View in: PubMed
    Score: 0.129
  30. The use of structured data elements to identify ASCVD patients with statin-associated side effects: Insights from the Department of Veterans Affairs. J Clin Lipidol. 2019 Sep - Oct; 13(5):797-803.e1.
    View in: PubMed
    Score: 0.127
  31. PCSK9 Inhibitors Prior Authorization. Circ Cardiovasc Qual Outcomes. 2019 08; 12(8):e005910.
    View in: PubMed
    Score: 0.127
  32. Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study. Eur J Prev Cardiol. 2020 10; 27(15):1597-1605.
    View in: PubMed
    Score: 0.127
  33. Mortality reduction with PCSK9 inhibition: A?case of cautious optimism. J Clin Lipidol. 2019 Sep - Oct; 13(5):712-713.
    View in: PubMed
    Score: 0.127
  34. Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry. Am Heart J. 2019 08; 214:113-124.
    View in: PubMed
    Score: 0.126
  35. Four Cases of Cholesterol Management Informed by the 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol. JAMA Cardiol. 2019 05 01; 4(5):473-477.
    View in: PubMed
    Score: 0.125
  36. ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change. Neurology. 2019 05 28; 92(22):e2580-e2593.
    View in: PubMed
    Score: 0.125
  37. Low-Density Lipoprotein Cholesterol: Is 160 the New 190? Circulation. 2018 11 20; 138(21):2326-2329.
    View in: PubMed
    Score: 0.121
  38. Measurement of Low-Density Lipoprotein Cholesterol Levels in Primary and Secondary Prevention Patients: Insights From the PALM Registry. J Am Heart Assoc. 2018 09 18; 7(18):e009251.
    View in: PubMed
    Score: 0.120
  39. Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease. J Am Coll Cardiol. 2018 07 10; 72(2):156-169.
    View in: PubMed
    Score: 0.118
  40. Frequency of Statin Use in Patients With Low-Density Lipoprotein Cholesterol =190 mg/dl from the Veterans Affairs Health System. Am J Cardiol. 2018 09 01; 122(5):756-761.
    View in: PubMed
    Score: 0.118
  41. Association of low-density lipoprotein pattern with mortality after myocardial infarction: Insights from the TRIUMPH study. J Clin Lipidol. 2017 Nov - Dec; 11(6):1458-1470.e4.
    View in: PubMed
    Score: 0.112
  42. Comparative effectiveness of outpatient cardiovascular disease and diabetes care delivery between advanced practice providers and physician providers in primary care: Implications for care under the Affordable Care Act. Am Heart J. 2016 Nov; 181:74-82.
    View in: PubMed
    Score: 0.104
  43. The Role of Ezetimibe in the Treatment of Cardiovascular Disease. Curr Atheroscler Rep. 2016 Feb; 18(2):8.
    View in: PubMed
    Score: 0.100
  44. Differential Lipid Response to Statins Is Associated With Variants in the BUD13-APOA5 Gene Region. J Cardiovasc Pharmacol. 2015 Aug; 66(2):183-8.
    View in: PubMed
    Score: 0.096
  45. Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry). Am J Cardiol. 2015 Aug 15; 116(4):547-53.
    View in: PubMed
    Score: 0.095
  46. Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry. J Am Coll Cardiol. 2014 Dec 02; 64(21):2183-92.
    View in: PubMed
    Score: 0.092
  47. Is high-intensity statin therapy associated with lower statin adherence compared with low- to moderate-intensity statin therapy? Implications of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guidelines. Clin Cardiol. 2014 Nov; 37(11):653-9.
    View in: PubMed
    Score: 0.091
  48. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2014 May; 34(5):1069-77.
    View in: PubMed
    Score: 0.087
  49. Novel therapies for treating familial hypercholesterolemia. Curr Atheroscler Rep. 2014 Jan; 16(1):382.
    View in: PubMed
    Score: 0.086
  50. Association between traditional cholesterol parameters, lipoprotein particle concentration, novel biomarkers and carotid plaques in retired National Football League players. Atherosclerosis. 2012 Jun; 222(2):551-6.
    View in: PubMed
    Score: 0.077
  51. Update on therapies targeting HDL: the mystery continues. Curr Opin Lipidol. 2011 Dec; 22(6):514-6.
    View in: PubMed
    Score: 0.075
  52. Relation of cholesterol and lipoprotein parameters with carotid artery plaque characteristics: the Atherosclerosis Risk in Communities (ARIC) carotid MRI study. Atherosclerosis. 2011 Dec; 219(2):596-602.
    View in: PubMed
    Score: 0.073
  53. Therapy and clinical trials: HDL-cholesterol and niacin therapy--past, present, and future. Curr Opin Lipidol. 2010 Apr; 21(2):165-6.
    View in: PubMed
    Score: 0.067
  54. Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study. J Am Coll Cardiol. 2009 Dec 15; 54(25):2388-95.
    View in: PubMed
    Score: 0.065
  55. Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association. J Clin Lipidol. 2024 Sep-Oct; 18(5):e647-e663.
    View in: PubMed
    Score: 0.045
  56. Long-Term Mortality in Patients With Severe Hypercholesterolemia Phenotype From a Racial and Ethnically Diverse US Cohort. Circulation. 2024 02 06; 149(6):417-426.
    View in: PubMed
    Score: 0.043
  57. Prevalence of familial hypercholesterolemia in a country-wide laboratory network in Pakistan: 10-year data from 988, 306 patients. Prog Cardiovasc Dis. 2023 Jul-Aug; 79:19-27.
    View in: PubMed
    Score: 0.042
  58. Novel therapies to achieve the recommended low-density lipoprotein cholesterol concentration (LDL-C) targets for patients after coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2024 02; 167(2):723-730.e4.
    View in: PubMed
    Score: 0.042
  59. The Effect of Yoga on Cardiovascular Disease Risk Factors: A Meta-Analysis. Curr Probl Cardiol. 2023 May; 48(5):101593.
    View in: PubMed
    Score: 0.040
  60. Burden and predictors of statin use in primary and secondary prevention of atherosclerotic vascular disease in the US: from the National Health and Nutrition Examination Survey 2017-2020. Eur J Prev Cardiol. 2022 10 20; 29(14):1830-1838.
    View in: PubMed
    Score: 0.040
  61. A stepwise approach to prescribing novel lipid-lowering medications. J Clin Lipidol. 2022 Nov-Dec; 16(6):822-832.
    View in: PubMed
    Score: 0.040
  62. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022 10 14; 43(39):3925-3946.
    View in: PubMed
    Score: 0.040
  63. Lipid-Lowering Therapy Use and Intensification Among United States Veterans Following Myocardial Infarction or Coronary Revascularization Between 2015 and 2019. Circ Cardiovasc Qual Outcomes. 2022 12; 15(12):e008861.
    View in: PubMed
    Score: 0.040
  64. Adherence to lipid monitoring and its impact on treat intensification of LDL-C lowering therapies at an urban academic medical center. J Clin Lipidol. 2022 Jul-Aug; 16(4):491-497.
    View in: PubMed
    Score: 0.039
  65. Midlife determinants of healthy cardiovascular aging: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2022 06; 350:82-89.
    View in: PubMed
    Score: 0.038
  66. Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis. Eur J Prev Cardiol. 2022 02 09; 28(18):2001-2009.
    View in: PubMed
    Score: 0.038
  67. Lipid Monitoring After Initiation of Lipid-Lowering Therapies: Return of Performance Measures? Curr Cardiol Rep. 2021 07 16; 23(9):116.
    View in: PubMed
    Score: 0.036
  68. How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol. Eur Heart J. 2021 06 07; 42(22):2154-2169.
    View in: PubMed
    Score: 0.036
  69. Dyslipidemia and Cardiovascular Disease Prevention in South Asians: A Review and Discussion of Causes, Challenges and Management Strategies. Curr Diabetes Rev. 2021; 17(9):e011221190238.
    View in: PubMed
    Score: 0.035
  70. Novel emerging therapies in atherosclerosis targeting lipid metabolism. Expert Opin Investig Drugs. 2020 Jun; 29(6):611-622.
    View in: PubMed
    Score: 0.034
  71. Pet Ownership and Cardiovascular Health in the US General Population. Am J Cardiol. 2020 04 15; 125(8):1158-1161.
    View in: PubMed
    Score: 0.033
  72. Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use: Insights From the Patient and Provider Assessment of Lipid Management Registry. JAMA Cardiol. 2018 08 01; 3(8):739-748.
    View in: PubMed
    Score: 0.030
  73. Case reports of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition nonresponse. J Clin Lipidol. 2018 Sep - Oct; 12(5):1141-1145.
    View in: PubMed
    Score: 0.029
  74. Updated Cost-effectiveness Assessments of PCSK9 Inhibitors From the Perspectives of the Health System and Private Payers: Insights Derived From the FOURIER Trial. JAMA Cardiol. 2017 12 01; 2(12):1369-1374.
    View in: PubMed
    Score: 0.028
  75. Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project. Am Heart J. 2018 01; 195:151-152.
    View in: PubMed
    Score: 0.028
  76. Use of high-intensity statins for patients with atherosclerotic cardiovascular disease in the Veterans Affairs Health System: Practice impact of the new cholesterol guidelines. Am Heart J. 2016 Dec; 182:97-102.
    View in: PubMed
    Score: 0.026
  77. Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis. Circulation. 2014 Jan 07; 129(1):77-86.
    View in: PubMed
    Score: 0.021
  78. A novel mutation in the ABCA1 gene causing an atypical phenotype of Tangier disease. J Clin Lipidol. 2013 Jan-Feb; 7(1):82-7.
    View in: PubMed
    Score: 0.020
  79. Lipid management: considerations in acute coronary syndrome. Curr Cardiol Rep. 2008 Jul; 10(4):334-41.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.